[Bronchial asthma: use of combination therapy. Anti-obstructive and anti-inflammatory treatment--result of treatment].
On the basis of a single case report, combined antiobstructive and anti-inflammatory treatment of bronchial asthma is described. The anti-obstructive component used was a sustained-release theophylline preparation (Euphylong, 750 mg/day), and as anti-inflammatory drug, the inhalant beclomethasone diproprionate (Viarox, 300 mg/day). During the 4-week treatment period, obvious improvements in lung function parameters (FEV1 from 21 prior to to 31 after treatment; FVC from 2.81 to 3.31) were seen. At a daily dose of 750 mg theophylline, a favorable therapeutic concentration of 16.5 micrograms/ml was achieved. It was found that the combination of sustained-release theophylline and the low-dose glucocorticoid inhalant resulted in an impressive improvement in bronchial asthma.
Zahn
T
T
D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D013806:Theophylline / Q000008:administration & dosage* / Q000009:adverse effects
D013806:Theophylline; D001507:Beclomethasone
Asthma bronchiale: Einsatz der Kombinationstherapie. Antiobstruktive und antiinflammatorische Behandlung--Behandlungsresultat.